Meet in Jinling | Shanghai Hycells Biotechnology Co., Ltd. cordially invites you to attend the 2024 IBI EXPO!
Release Date:
2024-05-07 14:14
Co-hosted by MedSail and Nanjing Biomedical Valley, the 2024 IBI EXPO Biopharmaceutical Innovation Drug Industry Conference focuses on the field of biologic innovative drugs, covering cutting-edge technological areas such as cell therapy, gene therapy, nucleic acid therapeutics, iPSC-based therapies, exosomes, novel antibodies, and organoids.
The 2024 IBI EXPO Biopharmaceutical Innovation Conference will be held at the Nanjing Yangtze River International Convention Center on June 14–15. As an exhibitor, Hycells Bio will showcase its flagship products and technology service platform to a wider audience of industry peers, and warmly welcomes collaboration and exchange with more partners and industry colleagues to jointly drive the advancement of the sector.
Recommended Star Products from Hycells Biotechnology
General-Purpose CAR Positive Rate Detection Tool
Anti-(G4S)n (B02H1) monoclonal antibody This CAR-wide detection reagent can directly identify and confirm the presence of CARs, regardless of their antigen specificity.
Product advantages of the CAR positivity rate detection tool:
1. Versatility It is a validated, universal CAR positivity assay that accelerates drug development by eliminating unnecessary and time-consuming steps.
2. Universality : Applicable to CAR assays for all targets (including (G4S)n, n≥2); CAR assays for different antibody types (including (G4S)n, n≥2).
3. Interference-free : Unaffected by antigen interference, enabling more accurate detection of the CAR ratio.
4. High sensitivity : Exhibits excellent detection efficiency at both extremely high and extremely low concentrations.
02
HiXpan TM γδ T Cell Expansion Kit
γδ T cells recognize tumor antigens in an MHC-independent manner, endowing them with the characteristics of a universal cell therapy product. With the successful completion of investigator-initiated trials and the emergence of approved clinical trial applications, γδ T-cell therapy has already emerged as a leading pipeline for next-generation allogeneic cell therapies.
HiXpan TM γδ T Cell Expansion Kit Product Advantages:
1. Pure factor amplification, Does not contain zoledronic acid ；
2. Use fresh or cryopreserved PBMCs as the starting cells to perform directed expansion of Vδ2 T cells, achieving a 200–300-fold expansion; the process is scalable in a linear fashion.
3. Amplification purity exceeds 90%, with high cytotoxic activity and high expression. CD56, NKG2D, HLA-DR ；
4. Possesses the ability to undergo continuous expansion within the body.
Highlights of the Conference
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board